| 摘要 |
The object of the invention is a composition for the treatment of bronchial asthma and chronic obstructive pulmonary disease, characterized in that the composition comprises phosphoethanolamine and Omega-3 folly acids in pre-established proportions. The preferred dose is 400 to 1200 mg/day, more specifically 800 mg/day for the phosphoethanolamine and 500 to 3200 mg/day, more specifically 1000 mg/day for the cicosapentaenoic acid 'EPA' and 350 to 2000 mg/day, more specifically 750 mg/day for the cocosahexaenoic acid 'DHA'.
|
